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tions, routine use remains controversial. We evaluated CIM
and compared graft patency in patients treated by surgeons
who performed routine CIM versus those who performed
selective CIM.
Methods: We reviewed the Vascular Study Group of
New England database(2003-2010) and assessed the use of
CIM(angiography and/or duplex) among patients under-
going LEB. Surgeon-specific CIM strategy was categorized
as selective(80% of LEB) versus routine(80% of LEB).
Exclusion criteria were acute limb ischemia, bilateral pro-
cedures, and surgeon volume 10 cases/study period.
Primary graft patency at discharge and 1-year were analyzed
based on CIM utilization and surgeon-specific CIM strat-
egy. Multivariable analyses were performed using Poisson
regression.
Results: Among 2032 LEB procedures performed by
48 surgeons, CIM was used in 1368 cases (67.3%). Dialysis
(OR 1.7, 95% CI 1.12-2.59, P  .01), elective LEB (OR
3.99, 95% CI 1.2-13.1, P  .02), great saphenous vein
conduit (OR 2.0, 95% CI 1.6-2.5, P  .0001), and tibial/
pedal target (OR 1.8, 95% CI 1.4-2.3, P  .0001) were
associated with CIM use. In multivariate models CIM was
not associated with improved graft patency at discharge
(OR 1.1, 95%CI: 0.7-1.7, P .64) or 1-year (OR 1.0, 95%
CI:0.8-1.4, P  .88). Sixteen surgeons(33%) were routine
and 32(67%) were selective CIM users. Discharge and
1-year graft patency was 96% versus 94% (P .21) and 68%
versus 72%(P  .09) in patients of routine versus selective
CIM users. In multivariate analysis, routine or selective
CIM strategy was not associated with improved discharge
(OR 0.8;95% CI:0.6-1.1; P  .3) or 1-year (OR 1.1; 95%
CI: 0.9-1.2; P  .56) graft patency.
Conclusions: In our observational cohort, surgeon-
specific strategy of selective CIM after LEB has comparable
outcomes with routine CIM. Use of selective rather than
routine CIM may lead to decreased health care resource
utilization.
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Objectives: Despite similar risk factors, women have
lower prevalence of PAD in the premenopausal period
compared with age-matched men. The prevalence of PAD
increases from 3-4% up to 29% in women after menopause.
By the 7th to 8th decades, the prevalence is comparable in
men and women. Little is known about the factors that
protect women from PAD prior to the onset of menopause.
The purpose of the study was to retrospectively review the
ABI and risk factor data in premenopausal ( 53 years of
age) women referred for ABI testing in the province of
Manitoba between 1993 and 2010.
Methods: In Manitoba, a province of 1.1 million,
virtually all ABI tests are performed at two hospitals by
trained technicians. Both sites also collect risk factor data.
ABI were considered to be abnormal if less than 0.9. Risk
factors included were smoking, coronary arterial disease,
obesity, diabetes, hypertension, hypercholesteremia, cere-
brovascular disease, and chronic renal failure.
Results: Between 1993 and 2010, 928 women under
the age of 53 underwent ABI testing (4.2% of all women in
the database). Of these, 260 had abnormal ABI (2.6%).
Eighty-five percent were between the ages of 41-52 and
27.9% had critically low ABI. The most prevalent risk for
premenopausal PAD in this population was current or
former smoking (85%). In most cases multiple coexisting
risk factors such as hypertension (57%), diabetes (55%), and
hyperlipidemia (55%) were present; however, no risk factor
other than smoking was present in 9.1% of women. In
premenopausal non-smokers, PAD did not develop unless
3 or more risk factors were present.
Conclusions: The development of premenopausal
PAD is unusual and does not develop without multiple
combined risk factors. Current and former smoking was
most associated with the development of premature PAD.
ABI testing in premenopausal women without multiple
combined risk factors, including smoking, is unlikely to be
of value.
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Objectives: To compare 30-day mortality and graft
failure after use of prosthetic graft (PG) versus vein graft
(VG) as conduit for extra-anatomic arterial bypass (EAB).
Methods: Patients who underwent axillary-femoral ar-
tery bypass (AFB) and femoral-femoral artery bypass (FFB)
grafts were identified from the 2007-09 National Surgical
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Quality Improvement Program (NSQIP) database. Multi-
variable logistic regression analysis was performed to iden-
tify preoperative factors associated with 30-day mortality
and graft failure.
Results: Of the 493 patients who underwent AFB, 89
(18.05%) received a VG and 404 (81.95%) received a PG.
Thirty-day mortality rates for patients receiving VG and PG
were 2.25% and 6.19%, respectively (P  .14) and graft
failure rates were 6.74% and 2.97%, respectively (P  .08).
On multivariate analysis, there was no difference in 30-day
mortality (odds ratio (OR)0.53; 95% confidence interval
(CI) 0.11-2.56) or graft failure rate (OR2.38; 0.77-
7.34) for patients receiving VG or PG for AFB.Of the 1219
patients who underwent FFB, 251(20.59%) received a VG
and 968 (79.41%) received a PG. Thirty-day mortality rates
for patients receiving VG and PG were 1.99% and 1.03%,
respectively (P .21) and graft failure rates were 3.98% and
1.65%, respectively (P  .04). On multivariate analysis,
there was no difference in 30-day mortality (OR1.45;
CI 0.38-5.59) or graft failure rate (OR2.19; CI 0.94-
5.08) for patients receiving VG or PG for FFB.
Conclusions: Thirty-day mortality and graft failure
rate are independent of the type of conduit used in patients
undergoing extra-anatomic arterial bypass.
Author Disclosures: M. Balters: Nothing to disclose; X.
Fang: Nothing to disclose;H. Gupta: Nothing to disclose;
P. K. Gupta: Nothing to disclose; J. M. Johanning:
Nothing to disclose; G. Longo: Nothing to disclose; T. G.
Lynch: Nothing to disclose; J. Mactaggart: Nothing to
disclose; B. Natarajan: Nothing to disclose; I. I. Pipinos:
Nothing to disclose.
PS102.
Comparison between Autologus Saphenous Vein and
Heparin-Bonded ePTFE Graft in the Treament of Crit-
ical Limb Ischemia: A Trans-Atlantic Experience
Walter Dorigo1, Raffaele Pulli1, Patrizio Castelli2, Vittorio
Dorrucci3, Fiore Ferilli4, Giovanni De Blasis5, Vincenzo
Monaca6, Enrico Vecchiati7, Richard Neville8, Carlo Pra-
tesi1. 1Vascular Surgery, University of Florence, Florence,
Italy; 2University of Insubria, Varese, Italy; 3Umberto I
Hospital, Venice-Mestre, Italy; 4Santa Maria Hospital,
Terni, Italy; 5SS. Filippo e Nicola Hospital, Avezzano,
Italy; 6V.E. Ferrarotto S. Bambino Hospital, Catania, Italy;
7S. Maria Nuova Hospital, Reggio Emilia, Italy; 8George
Washington University, Washington DC, DC
Objectives: To compare early and follow-up results of
below-knee bypasses performed with a bioactive heparin-
treated ePTFE graft and with autologous saphenous vein
(ASV) in patients with critical limb ischemia in a multicen-
tric retrospective registry involving eight Italian and Amer-
ican vascular centres.
Methods: Over a nine year period, ending in 2010, a
heparin bonded prosthetic graft (Propaten Gore-Tex®,
W.L. Gore & Associates Inc, Flagstaff, AZ) was implanted
in 461 patients undergoing below-knee revascularization
for critical limb ischemia in seven Italian and one American
hospitals (HePTFE group). In the same period of time in
these eight centres 376 below-knee bypasses with ipsilateral
ASV in patients with critical limb ischemia were performed
(ASV group). Early (30 days) results were analyzed in
terms of graft patency, major amputation rates and mortal-
ity. Follow-up results were analyzed in terms of primary and
secondary graft patency, limb salvage and survival.
Results: Early graft thrombosis occurred in 52 patients
(33 in HePTFE group and 19 in ASV group); there were
26 early major amputations (19 in HePTFE group and 7 in
ASV group), with 30-day major amputation rates of 3.9%
and 1.9%, respectively (P .09).Mean duration of follow-up
was 27.1  22.4 months. Primary patency rate at 48
months was significantly better in ASV group (61.8%) than
in HePTFE group (38.5%; P  .001, log rank 19.1). The
rates of secondary patency at 48 months were 51.9% in
HePTFE group and 65.9% in ASV group (P .02, log rank
52); the corresponding values in terms of limb salvage and
amputation free-survival rates were 74.4% and 78.9% (P 
.3, log rank 0.9), and 52.9% and 54% (P .6, log rank 0.2),
respectively.
Conclusions: Heparin-bonded ePTFE graft provides
satisfactory early and mid-term results in patients undergo-
ing surgical treatment of critical limb ischemia. While au-
tologous saphenous vein maintains its superiority in terms
of primary and secondary patency, limb salvage rates are
comparable.
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Objectives: This article reports the early human results
of HELP technology in the prevention of major limb
amputation due to ischemia. In short-term aim was to
dilate pre-existing collateral channels and the long-term
aim was to stimulate remodelling and new collateral devel-
opment by increasing endothelial shear stress.
Methods: A pilot study consisted of 20 patients with
critical limb ischemia. These patients had no other option
but major amputation as determined by at least two vascu-
lar surgeons. The ischemic limb was isolated from the
systemic circulation by the use of an implantable, inflatable,
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